Allergan this afternoon reported that fourth-quarter net profit rose on continued strong demand for its Botox anti-wrinkle treatment and other specialty pharmaceuticals.
California-based Allergan posted a net profit of $160.3 million, or 52 cents per share, compared with a profit of $136.8 million, or 45 cents per share, a year earlier.
Adjusted earnings from continuing operations were 60 cents per share. Analysts on average had expected 58 cents per share.